FABP4 and metabolic dysfunction-associated steatotic liver disease: FABP4-deficient mice exhibit severe insulin resistance [21], and NAFLD is known to be associated with an increased risk of other extrahepatic complications, including type 2 diabetes, fatal and non-fatal cardiovascular diseases (CVD), as well as incident chronic kidney diseases (CKD) [29].